Item no. |
ABC-ASC10936 |
Manufacturer |
Abcepta
|
Amount |
100 ug |
Category |
|
Type |
Antibody Primary |
Applications |
ELISA |
Specific against |
other |
Host |
Rabbit |
ECLASS 10.1 |
32160702 |
ECLASS 11.0 |
32160702 |
UNSPSC |
12352203 |
Available |
|
Primary Accession |
C4AL28 |
Application |
E |
Bio Background |
Swine H1N1 Neuraminidase Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups. |
Bio References |
Thompson WW, Shay DK, Weintraub, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA2003; 289:179-186.Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med.2009; 360:2605-15.Butler D. Swine flu goes global. Nature2009; 458:1082-3.Morens DM, Taubenberger JK, and Fauci AS. The Persistent Legacy of the 1918 Influenza Virus. N. Engl. J. Med.2009; Jun 29. |
Clonality |
Polyclonal |
Reactivity |
V |
Legend image 1 |
ELISA results using Swine H1N1 Neuraminidase antibody at 1 µg/mL and the blocking and corresponding peptides at 50, 10, 2 and 0 ng/mL. |
Other Accession |
ACQ76308; 229535824 |
Isotype |
IgG |
Antigen Source |
Influenza A virus (A/California/14/2009(H1N1)) |
Target/Specificity |
NA; This antibody is specific for the novel swine influenza Neuraminidase and will not recognize the corresponding Neuraminidase sequence from the seasonal H1N1 influenza (A/Georgia/20/2006 (H1N1)). Will not cross-react with peptide corresponding to the seasonal influenza (H1N1) Neuraminidase. |
Purification |
Swine H1N1 Neuraminidase Antibody is affinity chromatography purified via peptide column. |
Reconstitution & Storage |
Swine H1N1 Neuraminidase antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Antibody Form |
Liquid |
Application Notes |
Neuraminidase antibody can be used for the detection of the Neuraminidase protein from the H1N1 strain of swine influenza A in ELISA. It will detect 2 ng of free peptide at 1 µg/mL |
Positive Control |
; |
Buffer |
Swine H1N1 Neuraminidase Antibody is supplied in PBS containing 0.02% sodium azide. |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.